SuperNK®

SuperNK is a patented immunotherapy
With a culturing technology that mass produces 95% pure NK cells
with superior killing ability.

(Patented in the US, China and Korea and international PCT application in many countries)

NK Cell Culture Technology of SuperNK®

Existing NK cell culture technologies mainly use highly concentrated cytokines, which only increase the number of NK cells (proliferation). SuperNK’s novel cell culture technology uses cytotoxicity enhancing agents and proliferating agents that the result is both highly cytotoxic and a large number of NK cells.
SuperNK® has unique patented NK cell culture technology.

Existing NK cell culture technology

Treatment with cytokine - Simple culture method (Simple proliferation of NK cells)

Novel NK cell culture technology

Treatment with cytokine and cell killing activity enhancer - Novel complex culture method (Proliferation of highly active (cytotoxic) NK cells)

Larger production

NK cells can be multiplied by 1,000 to 10,000 folds through a patented culturing technology.

Change in the Number of NK Cells during the culture

High Purity of NK Cells

The purity of NK cells is increased to 95% through NKMAX’s culturing process.

Comparison of NK Cell Purity before & after Culturing

Improved cancer cell killing ability

The culturing process reinforces the ability to kill cancer cells.

Comparison of Cancer Cell killing ability before & after Culturing

Effector cell(Super NK):Target cell(K562 cell line) ratio = 1:1

Improved immune activity

The culturing process reinforces immune function.

Comparison of Cytokine Secretion before & after Culturing

Superiority of SuperNK®

The novel potential immunotherapy that overcomes the limitations of the existing NK cell therapy

Limitation of existing NK cell therapies	Superiority of SuperNK®
Generally display decreased killing ability	Killing ability improved SuperNK cells display superior cell killing ability at lower ratios.
Lower NK cell purity containing a large portion of other immune cells	High purity of NK cells SuperNK contains NK cells with a purity of 95%.
Difficult in vitro mass production	Mass production available Through SNK’s patented culturing technology, NK cells proliferate from 5,000 to 19 billion folds.
Ineffective treatment due to inhibition of Immune function in cancer patients	Better survival and activity in cancer patients. Produces enough cytotoxic cells for increased survival/activity to overcome cancer patients’ immune inhibitory environment.

Immunotherapy

SuperNK® 100mL (1 bag), 2-6 billion NK cells intravenous injection

① Blood draw (White blood cell collection)
② Obtain NK cells - NK cells separated from blood
③ Incubate as highly active NK cells - Expansion of NK cells with high killing ability and activity
④ In-vitro mass production - Mass production of healthy donor and cancer patient NK cells available

① 60ml peripheral blood draw
② NK cells separated from blood - Technology of SuperNK® immunotherapy
③ Inducing of NK cell expansion
④ Mass production of highly activated NK cells with 95% purity or more, up to average of 5,000 (autologous) ~ 10 billion (allogenic) times higher - Technology of SuperNK® immunotherapy